Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients
Sponsor: RenJi Hospital
Summary
This study is a randomized, double-blind, placebo-controlled single-center clinical trial. The aim of this study is to investigate the efficacy and safety of low-dose telitacicept for prevention of flares in SLE patients with low disease activity.
Official title: A Randomized, Double-blind, Placebo-controlled Trial of Efficacy and Safety of Low-dose Telitacicept for Prevention of Flares in SLE Patients With Low Disease Activity
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
176
Start Date
2024-06-28
Completion Date
2027-06-30
Last Updated
2024-07-03
Healthy Volunteers
No
Conditions
Interventions
Telitacicept
Telitacicept 160 mg SC every other week
Placebo
Placebo to Telitacicept
Locations (1)
Ren Ji Hospital
Shanghai, China